Literature DB >> 21606483

Human T cells expressing affinity-matured TCR display accelerated responses but fail to recognize low density of MHC-peptide antigen.

Sharyn Thomas1, Shao-An Xue, Charles R M Bangham, Bent K Jakobsen, Emma C Morris, Hans J Stauss.   

Abstract

We have tested whether affinity-matured TCRs that retain peptide specificity improve the ability of primary human CD8(+) T cells to mount antigen-specific responses. We found that TCR affinity correlated with the speed of T-cell responses. High affinity TCR-antigen interactions rapidly initiated T-cell responses, but low affinity TCR/antigen interactions required longer time periods to elicit the same responses. Within the "natural" affinity range, increased TCR-to-antigen affinity correlated with improved ability of T cells to recognize low concentration of antigen. However, affinity-matured TCR with 700-fold enhanced affinity for MHC-to-antigen required 100-fold higher antigen-density to initiate T-cell responses than did wild-type TCR. Using modified peptides to reduce the affinity of TCR-to-antigen interaction, we demonstrate that affinity-matured TCRs are not defective, being superior to wild-type TCR in recognizing low concentration of modified peptides. These data indicate that enhancing TCR affinity can accelerate the speed of T-cell activation and reduce the ability to recognize low density of MHC-to-peptide antigen. We predict that future studies of the human T-cell repertoire will reveal 2 types of low avidity T cells: fast and slow responders, with high-affinity and low-affinity TCR, respectively.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21606483     DOI: 10.1182/blood-2010-12-326736

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  48 in total

1.  Photocrosslinkable pMHC monomers stain T cells specifically and cause ligand-bound TCRs to be 'preferentially' transported to the cSMAC.

Authors:  Jianming Xie; Johannes B Huppa; Evan W Newell; Jun Huang; Peter J R Ebert; Qi-Jing Li; Mark M Davis
Journal:  Nat Immunol       Date:  2012-06-03       Impact factor: 25.606

2.  T Cell Reprogramming Against Cancer.

Authors:  Samuel G Katz; Peter M Rabinovich
Journal:  Methods Mol Biol       Date:  2020

Review 3.  Structural and biophysical determinants of αβ T-cell antigen recognition.

Authors:  John S Bridgeman; Andrew K Sewell; John J Miles; David A Price; David K Cole
Journal:  Immunology       Date:  2012-01       Impact factor: 7.397

4.  Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsiveness.

Authors:  Melita Irving; Vincent Zoete; Michael Hebeisen; Daphné Schmid; Petra Baumgartner; Philippe Guillaume; Pedro Romero; Daniel Speiser; Immanuel Luescher; Nathalie Rufer; Olivier Michielin
Journal:  J Biol Chem       Date:  2012-05-01       Impact factor: 5.157

Review 5.  Engineering CAR-T cells: Design concepts.

Authors:  Shivani Srivastava; Stanley R Riddell
Journal:  Trends Immunol       Date:  2015-07-11       Impact factor: 16.687

6.  Leveraging TCR Affinity in Adoptive Immunotherapy against Shared Tumor/Self-Antigens.

Authors:  Aaron M Miller; Milad Bahmanof; Dietmar Zehn; Ezra E W Cohen; Stephen P Schoenberger
Journal:  Cancer Immunol Res       Date:  2018-11-27       Impact factor: 11.151

7.  Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice.

Authors:  Xiaojun Liu; Shuguang Jiang; Chongyun Fang; Shiyu Yang; Devvora Olalere; Edward C Pequignot; Alexandria P Cogdill; Na Li; Melissa Ramones; Brian Granda; Li Zhou; Andreas Loew; Regina M Young; Carl H June; Yangbing Zhao
Journal:  Cancer Res       Date:  2015-09-01       Impact factor: 12.701

8.  Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity.

Authors:  Hillary G Caruso; Lenka V Hurton; Amer Najjar; David Rushworth; Sonny Ang; Simon Olivares; Tiejuan Mi; Kirsten Switzer; Harjeet Singh; Helen Huls; Dean A Lee; Amy B Heimberger; Richard E Champlin; Laurence J N Cooper
Journal:  Cancer Res       Date:  2015-09-01       Impact factor: 12.701

9.  SHP-1 phosphatase activity counteracts increased T cell receptor affinity.

Authors:  Michael Hebeisen; Lukas Baitsch; Danilo Presotto; Petra Baumgaertner; Pedro Romero; Olivier Michielin; Daniel E Speiser; Nathalie Rufer
Journal:  J Clin Invest       Date:  2013-02-08       Impact factor: 14.808

Review 10.  T-cell receptor gene therapy--ready to go viral?

Authors:  Terhi Karpanen; Johanna Olweus
Journal:  Mol Oncol       Date:  2015-10-20       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.